The GABA-A receptor is the principal target of most clinically used GABAergic anti-seizure drugs (ASDs). Its pentameric architecture and the extraordinary diversity of its subunit combinations produce a family of receptor subtypes with distinct pharmacological profiles, regional distributions, and susceptibilities to different drug classes. Understanding this subunit pharmacology is essential for interpreting the mechanistic differences between benzodiazepines, barbiturates, and newer allosteric modulators.
The GABA-A receptor is a ligand-gated ion channel of the Cys-loop superfamily, assembled as a pentamer from a large family of subunit proteins. Nineteen subunit genes have been identified in mammals, encoding alpha (alpha1–alpha6), beta (beta1–beta3), gamma (gamma1–gamma3), delta, epsilon, theta, pi, and rho subunits. The most abundant native receptor isoform in the brain contains two alpha1, two beta2, and one gamma2 subunit, assembled with pseudo-symmetry around a central chloride-conducting pore. The GABA binding sites are located at the interfaces between alpha and beta subunits, and the receptor is activated when both sites are occupied by GABA.1 Chloride ions flow down their electrochemical gradient into the postsynaptic neuron upon channel opening, hyperpolarizing the membrane and increasing the threshold for action potential generation. This inhibitory postsynaptic potential (IPSP) constitutes the primary fast inhibitory signal in the central nervous system (CNS).
The gamma2 subunit is a structural requirement for benzodiazepine sensitivity. The benzodiazepine binding site is located at the interface between the alpha and gamma2 subunits, and the identity of the alpha subunit present determines the functional profile of benzodiazepine action. Receptors containing alpha1, alpha2, alpha3, or alpha5 subunits paired with a gamma2 subunit are benzodiazepine-sensitive, while receptors containing alpha4 or alpha6 subunits are insensitive to classical benzodiazepines. The alpha1-containing receptors mediate sedation, anterograde amnesia, and anticonvulsant effects, while alpha2-containing receptors are more important for anxiolytic and muscle relaxant effects. This pharmacological dissociation has driven efforts to develop alpha-subunit-selective modulators, though no clinically marketed benzodiazepine achieves this selectivity.2
Barbiturates bind to a distinct site on the GABA-A receptor, located within the transmembrane domain at the beta-alpha subunit interface, separate from both the GABA binding site and the benzodiazepine site. The barbiturate binding site is present on virtually all GABA-A receptor isoforms, which accounts for the broader, less selective CNS depression that characterizes barbiturate use compared with benzodiazepines. Barbiturates produce their effects primarily by prolonging the duration of chloride channel opening events rather than increasing their frequency as benzodiazepines do, and at high concentrations they can directly activate the chloride channel in the absence of GABA. This direct activation is the molecular basis of barbiturate-induced respiratory depression at supratherapeutic doses, since respiratory brainstem neurons cannot be protected by endogenous GABA depletion once the drug can open channels without GABA. The absence of this direct activation property in benzodiazepines is the mechanistic reason why benzodiazepine overdose alone rarely causes fatal respiratory depression when the airway is protected.3
The delta subunit, which substitutes for gamma2 in extrasynaptic receptors containing alpha4 or alpha6 subunits, confers sensitivity to neurosteroids and to the anesthetic properties of etomidate, but does not bind classical benzodiazepines. Delta-containing receptors mediate tonic inhibition rather than phasic synaptic inhibition, responding to sustained low ambient GABA concentrations in the extracellular space. Tonic inhibition is an important regulator of neuronal excitability in hippocampus, cerebellum, and thalamus, and some newer investigational compounds target this tonic inhibitory system as a distinct anti-seizure strategy separate from synaptic GABA potentiation.
Sustained seizure activity causes rapid internalization of synaptic GABA-A receptors containing gamma2 subunits, reducing the number of benzodiazepine-sensitive receptors at the synaptic membrane. Simultaneously, NMDA receptors are inserted into the synapse, shifting the excitatory-inhibitory balance further toward excitation. This receptor trafficking, which begins within 30–60 minutes of continuous seizure activity, explains the well-documented reduction in benzodiazepine efficacy with prolonged status epilepticus (SE). It is the pharmacodynamic basis for the time-urgency of SE treatment: benzodiazepines given within the first 10–30 minutes of SE have substantially higher efficacy than the same doses given after 60 minutes, independent of any pharmacokinetic considerations. Early, adequate dosing is not merely faster -- it is fundamentally more effective.
Benzodiazepines are the first-line pharmacological treatment for acute seizures and status epilepticus across all settings, from the prehospital environment to the intensive care unit. Their high efficacy, rapid onset, and relative safety margin make them indispensable. Understanding why they differ from one another in clinical application requires attention to their pharmacokinetic profiles, which span a wide range of onset times, redistribution patterns, half-lives, and active metabolite burdens.
All benzodiazepines act as positive allosteric modulators (PAMs) at GABA-A receptors. They bind at the interface between alpha and gamma2 subunits and, in the presence of GABA, increase the frequency of chloride channel opening without affecting channel conductance or open duration. This frequency-enhancement mechanism amplifies the effect of synaptically released GABA rather than generating inhibitory currents independently. The obligate requirement for GABA means that benzodiazepine effects are self-limiting at synapses where presynaptic GABA has been depleted, providing an intrinsic ceiling on their depressant effects under physiological conditions. This is the pharmacodynamic basis of their substantially greater therapeutic index compared with barbiturates, which can generate inhibitory chloride currents independently of GABA.2
Diazepam is the prototypical benzodiazepine for acute seizure treatment, with several features that make it particularly suitable for the prehospital and emergency setting. It is highly lipophilic, crossing the blood-brain barrier (BBB) rapidly after intravenous (IV) administration and achieving effective CNS concentrations within 1–3 minutes. However, diazepam's high lipophilicity also drives rapid redistribution from the CNS into peripheral fat compartments, which terminates its acute anticonvulsant effect long before its pharmacokinetic half-life of 20–100 hours would predict. This redistribution-driven termination of effect means that a single IV dose of diazepam achieves seizure control that lasts only 20–30 minutes in practice, even though the parent drug and its principal active metabolite, desmethyldiazepam (nordazepam), persist in the body for days. Rectal diazepam gel and intranasal diazepam formulations have been developed for out-of-hospital use in patients with seizure clusters or acute prolonged seizures who cannot receive IV administration.4
Lorazepam has largely supplanted diazepam as the preferred IV agent for SE in many hospital settings because of pharmacokinetic advantages that translate directly to superior clinical performance. Lorazepam is substantially less lipophilic than diazepam and has lower plasma protein binding. These properties result in a smaller volume of distribution and slower redistribution from the CNS after IV administration, producing a duration of anticonvulsant effect of 12–24 hours rather than the 20–30 minutes seen with diazepam. Lorazepam does not have clinically significant active metabolites and its half-life of 10–20 hours is shorter than diazepam's. In the Randomized Prehospital Comparison of Benzodiazepine Trials (RAMPART) study, intramuscular (IM) midazolam was shown to be non-inferior to IV lorazepam for SE, with the significant practical advantage that IM administration is faster than IV placement in the prehospital setting.5
Midazolam is unique among the benzodiazepines used in SE management in its water solubility at low pH, which allows formulation as an aqueous solution suitable for IM, intranasal, and buccal administration, in addition to the IV route. After IM injection, midazolam is absorbed rapidly, with peak plasma concentrations reached in 10–20 minutes. Its half-life of 1–4 hours is the shortest among commonly used benzodiazepines, and it has no pharmacologically active metabolites at standard clinical doses. Midazolam is metabolized entirely by CYP3A4 to 1-hydroxymidazolam, which is then glucuronidated and excreted renally. The RAMPART study established IM midazolam at 10 mg as the first-line prehospital treatment for convulsive SE, demonstrating superior seizure cessation rates compared with IV lorazepam when accounting for the time required to establish IV access in the field.5
Clonazepam occupies an important niche in chronic epilepsy management, particularly for myoclonic and absence seizures in patients with juvenile myoclonic epilepsy (JME) and other idiopathic generalized epilepsies (IGEs). It has a half-life of 30–40 hours, allowing twice-daily dosing. Clobazam, a 1,5-benzodiazepine (compared with the 1,4-benzodiazepine structure of most agents in the class), has been approved in many countries as adjunctive therapy for Lennox-Gastaut syndrome (LGS). Its 1,5-isomeric structure confers less prominent sedation at anticonvulsant doses compared with 1,4-benzodiazepines, which has clinical relevance in the pediatric population with LGS where cognitive burden is already a significant concern. Clobazam is metabolized to N-desmethylclobazam, an active metabolite with a half-life of approximately 60–70 hours that contributes substantially to its anticonvulsant effect.6
Continuous or frequent benzodiazepine exposure leads to tolerance through multiple mechanisms: internalization of GABA-A receptors from the synaptic membrane, changes in receptor subunit composition that reduce benzodiazepine sensitivity, and compensatory upregulation of NMDA receptor expression. Tolerance to sedation and anticonvulsant effects typically develops within days to weeks of continuous use. Tolerance to anxiolytic effects is more variable. Abrupt discontinuation after physical dependence has developed precipitates a withdrawal syndrome characterized by rebound anxiety, insomnia, autonomic instability, and in severe cases, seizures -- even in patients without epilepsy. The paradox of treating epilepsy with drugs that can themselves cause withdrawal seizures underscores the need for gradual dose reduction when benzodiazepines are being discontinued. In long-term epilepsy management, clonazepam "drug holidays" or intermittent dosing strategies have been used to partially delay tolerance development, though evidence for these approaches is limited.
Diazepam (IV, rectal, intranasal): Rapid onset, but redistribution terminates effect in 20–30 min. Long half-life (20–100 h) with active metabolites (nordazepam). Best for initial control when IV access is available; rectal/intranasal gel for home use in seizure clusters.
Lorazepam (IV): Less lipophilic than diazepam; slower redistribution; sustained CNS effect 12–24 h. No active metabolites. Preferred IV agent in-hospital for SE; produces more reliable prolonged seizure control than diazepam.
Midazolam (IM, intranasal, buccal, IV): Water-soluble; fastest IM absorption. Half-life 1–4 h; no active metabolites. Prehospital first-line IM agent (RAMPART). Intranasal and buccal formulations for community use.
Clonazepam (oral): Half-life 30–40 h. Long-term adjunct for myoclonic, absence, and atonic seizures in IGEs.
Clobazam (oral): 1,5-isomer; less sedating. Active metabolite N-desmethylclobazam (t½ approximately 60–70 h). Adjunctive therapy for LGS.
Phenobarbital, introduced in 1912, is one of the oldest anti-seizure drugs still in widespread clinical use worldwide. Its continued relevance reflects both its broad efficacy across seizure types and its low cost relative to newer agents. In high-income settings, cognitive and behavioral adverse effects have driven most practitioners toward alternative agents as first-line therapy, but phenobarbital remains indispensable for parenteral seizure management and is the most widely used ASD globally by total patient volume.15
Phenobarbital's primary mechanism of action at the GABA-A receptor is qualitatively distinct from benzodiazepine action in two important ways. First, phenobarbital binds at the barbiturate site on the transmembrane beta-alpha interface rather than the alpha-gamma2 benzodiazepine site, and it acts by prolonging the duration of individual chloride channel opening events rather than increasing their frequency. The result is a larger conductance integral per channel opening, producing stronger inhibition per receptor activation. Second, at supratherapeutic concentrations, phenobarbital can directly open the GABA-A receptor chloride channel in the complete absence of GABA. This direct activation property, absent in benzodiazepines, removes the endogenous GABA ceiling and is responsible for both phenobarbital's usefulness in refractory SE (where synaptic GABA may be depleted) and its narrow therapeutic index compared with benzodiazepines.3 Phenobarbital also has a secondary mechanism: it reduces glutamate-mediated excitatory neurotransmission by inhibiting AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate receptor responses, contributing to its broad anticonvulsant profile.
The pharmacokinetics of phenobarbital are characterized by complete oral bioavailability, low plasma protein binding of approximately 45–50%, and a long half-life of 75–120 hours. This long half-life requires 2–4 weeks to reach steady state after initiating or changing a dose, and it provides the significant clinical advantage of minimal fluctuation in plasma concentrations with standard dosing intervals. Once-daily dosing is appropriate for most patients. Phenobarbital is metabolized primarily by CYP2C9 and CYP2C19, with a fraction excreted unchanged in urine. It is one of the most potent enzyme inducers among all ASDs, upregulating CYP1A2, CYP2C9, CYP2C19, CYP3A4, and UGT enzymes to a degree comparable to carbamazepine and phenytoin. The therapeutic range is generally accepted as 15–40 mg/L (65–172 micromol/L), though individual patients may tolerate and require concentrations outside this range.7
Phenobarbital is an effective ASD for focal onset seizures, generalized tonic-clonic seizures, and febrile seizures. It is also used intravenously as a third-line agent for refractory SE, following failure of both benzodiazepines and a second-stage agent (fosphenytoin, valproate, or levetiracetam). In this refractory SE context, phenobarbital at doses of 20 mg/kg IV produces blood levels sufficient to directly activate GABA-A channels, providing seizure control that does not depend solely on endogenous GABA. However, at the doses required for refractory SE, significant respiratory depression and hypotension occur, necessitating mechanical ventilation and hemodynamic support. The IV formulation uses propylene glycol as a vehicle, with infusion rate limited to 60–100 mg/min to reduce cardiac and respiratory toxicity from the vehicle.14
Primidone is a structural analogue of phenobarbital that is itself active at GABA-A receptors, but a substantial component of its anticonvulsant effect is attributable to its metabolism to phenobarbital by CYP2C9. The third metabolite, phenylethylmalonamide (PEMA), also has some anticonvulsant activity. When primidone is initiated, patients experience both the direct effects of primidone and, after several days as enzyme induction stabilizes, the effects of accumulating phenobarbital. This metabolic relationship means that patients established on primidone essentially receive a combination of primidone and phenobarbital, and converting between the two drugs requires careful pharmacokinetic consideration. Primidone shares phenobarbital's adverse effect profile, including sedation, cognitive impairment, and enzyme induction, and offers no clear advantage over phenobarbital in most clinical settings. Its primary remaining role is in the treatment of essential tremor, where it is often preferred over phenobarbital.8
Phenobarbital is included on the World Health Organization (WHO) Model List of Essential Medicines and costs only a few cents per tablet in most low- and middle-income countries (LMICs). The treatment gap for epilepsy in LMICs exceeds 75% in many regions, and phenobarbital is the only ASD accessible to large segments of this population. The same drug that has fallen from favor in high-income settings due to cognitive effects is the primary tool available for preventing seizure-related injury, status epilepticus, and death in the developing world. This access paradox frames phenobarbital as simultaneously a medication with an unfavorable risk-benefit profile in settings where alternatives exist, and a life-saving essential medicine where alternatives do not exist. Prescribers practicing in or consulting for resource-limited settings should be familiar with phenobarbital's clinical pharmacology.
Vigabatrin and tiagabine both enhance GABAergic inhibition by mechanisms upstream of the GABA-A receptor itself, increasing the availability of GABA at the synapse rather than potentiating its receptor-level effects. Both agents have highly restricted clinical applications, and both carry serious adverse effect risks that limit their use to specific patient populations. Understanding their mechanisms clarifies why GABA enhancement by these indirect routes produces different pharmacological profiles from direct receptor modulation.
Vigabatrin (gamma-vinyl GABA) is a structural analogue of GABA that irreversibly inhibits GABA transaminase (GABA-T), the mitochondrial enzyme responsible for the catabolism of synaptic GABA back to succinic semialdehyde. By irreversibly inactivating GABA-T through a mechanism-based suicide inhibition (the vinyl group reacts covalently with the enzyme's pyridoxal phosphate cofactor), vigabatrin prevents GABA breakdown and allows GABA to accumulate at synaptic and extrasynaptic sites. Because the inhibition is irreversible, recovery of GABA-T activity requires de novo enzyme synthesis, which takes days to weeks after the drug is discontinued. This sustained elevation of synaptic GABA concentrations is the basis of vigabatrin's antiseizure effect, which is particularly pronounced in focal epilepsies and infantile spasms (West syndrome).9
Vigabatrin is approved in the United States specifically for infantile spasms (IS) in patients 1 month to 2 years of age and as adjunctive therapy for refractory complex partial seizures (focal impaired awareness seizures) in adults. In infantile spasms, vigabatrin is the treatment of choice for patients with tuberous sclerosis complex (TSC)-associated IS, where it substantially outperforms corticotropin (ACTH) in terms of IS cessation rates and EEG normalization. For IS not associated with TSC, ACTH remains an alternative first-line choice. The very specific indication for IS reflects vigabatrin's superior efficacy in this syndrome rather than broad anticonvulsant properties across seizure types.9
Vigabatrin's use is severely restricted by a mandatory risk evaluation and mitigation strategy (REMS) program in the United States due to irreversible bilateral concentric visual field constriction (BVFC), which occurs in approximately 30% of adults and an uncertain proportion of infants on vigabatrin. The mechanism of BVFC involves GABA accumulation in the retina, where GABAergic signaling between amacrine cells and bipolar cells normally modulates retinal ganglion cell output. Excess GABA disrupts this signaling, causing progressive loss of peripheral vision that is typically asymptomatic until substantial field loss has occurred, and that does not reverse after drug discontinuation. All patients on vigabatrin must undergo baseline and periodic visual field testing (every 3 months), and the drug should be discontinued if visual field loss is detected.10 Infants cannot perform standard perimetry and must be monitored by electroretinography (ERG) or visual evoked potentials (VEPs). The irreversibility of the visual toxicity means that monitoring does not prevent harm -- it detects harm early enough to prevent additional loss.
Tiagabine is a selective inhibitor of GABA transporter 1 (GAT-1), the primary neuronal and glial reuptake transporter responsible for clearing released GABA from the synapse. By blocking GAT-1, tiagabine prolongs the time GABA remains in the synaptic cleft after release, enhancing GABA-A receptor activation by extending receptor exposure to synaptically released GABA. This mechanism is conceptually similar to how serotonin reuptake inhibitors extend serotonergic signaling, but applied to the GABAergic synapse. Tiagabine is approved as adjunctive therapy for partial onset seizures in adults and adolescents aged 12 years and older. Its clinical use has declined substantially due to its adverse effect profile and a serious risk discussed below.11
The most clinically consequential hazard associated with tiagabine is its capacity to induce non-convulsive status epilepticus (NCSE) in patients who do not have a pre-existing epilepsy diagnosis. This was discovered after tiagabine was prescribed off-label for psychiatric indications including anxiety disorders and bipolar disorder, where clinicians unfamiliar with its ASD-specific risks were using it in patients without epilepsy. The mechanism likely involves inappropriate GABA enhancement in cortical circuits where background activity is near-ictal, tipping the balance into NCSE. The clinical presentation of tiagabine-induced NCSE includes confusion, behavioral change, and psychomotor slowing without convulsions, and EEG confirmation is required for diagnosis. This risk, combined with tiagabine's narrow therapeutic window and requirement for multiple daily doses (it has a half-life of only 5–8 hours), has made it one of the least commonly used ASDs in current practice. It should not be used in patients who do not have established epilepsy.11
The vigabatrin REMS program requires enrollment of both prescribers and patients before the drug can be dispensed. Prescribers must document visual field testing at baseline, then every 3 months during treatment, and 3–6 months after discontinuation. In infants, ERG is recommended at baseline and every 3 months. Patients must be counseled that visual field deficits are irreversible and will not improve after stopping the drug. The decision to continue vigabatrin must be reassessed at each monitoring visit using a formal benefit-risk assessment -- the drug should be discontinued if the patient is not responding adequately to therapy, since the visual risk is only justified by meaningful seizure reduction. No ophthalmological baseline or monitoring requirements distinguish vigabatrin from all other currently used ASDs, making it the most ophthalmologically demanding agent in the class.
GABAergic agents collectively represent the most acutely effective pharmacological tools available for seizure control, but they carry class-specific adverse effects centered on CNS depression, cognitive impairment, and physical dependence. The clinical skill in using these agents lies in matching the right drug, dose, and route to the clinical situation, while anticipating and managing the predictable adverse consequences of GABAergic enhancement.
The management of convulsive SE follows a time-sensitive escalating protocol based on the principle that each additional 10 minutes of untreated seizure activity reduces the probability of benzodiazepine efficacy and increases the risk of permanent neurological injury. Phase 1 (0–5 minutes): IV lorazepam 0.1 mg/kg (maximum 4 mg per dose) or IM midazolam 10 mg (adult), repeated once if no response. Intranasal midazolam (0.2 mg/kg, maximum 10 mg) and rectal or intranasal diazepam are alternatives when IV access is unavailable. Phase 2 (benzodiazepine failure, typically 10–30 minutes): IV fosphenytoin, IV valproate, or IV levetiracetam at weight-based loading doses -- these three have equivalent efficacy as established by the ESETT trial. Phase 3 (failure of two agents): IV phenobarbital 20 mg/kg, or transition to continuous infusion anesthetic agents (propofol, midazolam, or pentobarbital) with continuous EEG monitoring in the intensive care unit (ICU). The transition from Phase 2 to Phase 3 represents refractory SE, defined as persistent seizures or EEG ictal activity despite adequate dosing of a first- and second-stage agent.12
The acute adverse effects of all GABAergic ASDs reflect their mechanism of enhancing CNS inhibition. Sedation is the most common and dose-dependent effect, ranging from mild drowsiness at low doses to general anesthesia at high doses of barbiturates and benzodiazepine infusions. Respiratory depression is the most dangerous acute adverse effect. Benzodiazepines cause respiratory depression primarily through cortical and brainstem mechanisms, but their dependence on endogenous GABA for effect provides a degree of self-limitation that makes fatal respiratory depression from benzodiazepines alone uncommon in individuals with intact respiratory drive. In contrast, barbiturate-induced respiratory depression can be profound at therapeutic anticonvulsant doses in the SE setting, and mechanical ventilation is routinely required when phenobarbital is used for refractory SE. The opioid reversal agent naloxone is not effective for benzodiazepine reversal; flumazenil, a competitive benzodiazepine receptor antagonist, can rapidly reverse benzodiazepine sedation and respiratory depression, but its short half-life of 1 hour means that resedation occurs after a single dose in patients with residual circulating benzodiazepine, and repeated dosing or infusion may be needed.13
The chronic adverse effects of barbiturates, particularly phenobarbital, include dose-related sedation, impaired processing speed and memory, behavioral changes (hyperactivity and irritability in children, depression in adults), and connective tissue complications including Dupuytren contracture and shoulder-hand syndrome with very long-term use. Vitamin D deficiency and osteomalacia occur due to CYP enzyme-induced accelerated vitamin D catabolism, and supplementation is generally recommended for patients on long-term barbiturate therapy. Benzodiazepine-specific long-term concerns include anterograde amnesia (encoding of new memories is impaired during active drug effect), physical dependence, and cognitive effects that may persist for months after discontinuation in long-term users. The extent of permanent cognitive impairment from prolonged benzodiazepine use remains debated in the literature, with some prospective studies finding recovery over months of abstinence and others documenting persistent deficits.
Vigabatrin's adverse effect profile beyond the irreversible visual toxicity includes sedation, weight gain, behavioral disturbance (agitation, depression, rarely psychosis), and peripheral neuropathy with long-term use. The behavioral adverse effects are particularly relevant in the pediatric IS population, where vigabatrin may be the most effective option but where behavioral monitoring must accompany visual monitoring. Tiagabine's adverse effects include dizziness, tremor, nervousness, and difficulty concentrating, in addition to the NCSE risk. Its short half-life requires three to four daily doses for adequate seizure control, adding adherence burden relative to longer-acting agents.
Abrupt discontinuation of benzodiazepines after prolonged use at anticonvulsant doses can precipitate a withdrawal syndrome that includes anxiety, tremor, diaphoresis, tachycardia, and generalized tonic-clonic seizures. The seizure threshold can drop so dramatically that patients without prior epilepsy experience their first-ever seizures during benzodiazepine withdrawal. In patients with epilepsy, breakthrough seizures during withdrawal may be difficult to distinguish from disease breakthrough. Management of benzodiazepine withdrawal in epilepsy patients requires a slow taper, typically reducing the dose by no more than 5–10% per week, with more gradual reduction in the lower dose range where the proportional reduction in GABA-A receptor activation is relatively larger. Phenobarbital substitution is an effective withdrawal strategy for severe benzodiazepine dependence, taking advantage of cross-tolerance between benzodiazepines and barbiturates at the GABA-A receptor.
Acute seizure prehospital: IM midazolam 10 mg (adult) or weight-based buccal/intranasal midazolam -- fastest route to effective CNS levels without IV access.
Acute seizure or SE in-hospital (IV access): IV lorazepam 0.1 mg/kg as first-line first-stage agent. Repeat once if no response within 5 minutes.
Refractory SE (Phase 3): IV phenobarbital 20 mg/kg over 30 minutes. Mechanically ventilate; monitor hemodynamics continuously.
Chronic adjunct, JME or IGE with myoclonic component: clonazepam as adjunct to valproate or levetiracetam. Begin low (0.25 mg at bedtime) and titrate slowly to minimize sedation and tolerance risk.
Adjunct therapy in LGS: clobazam, taking advantage of its reduced sedation relative to 1,4-benzodiazepines and its long-acting metabolite.
Infantile spasms (TSC-associated): vigabatrin with mandatory visual monitoring -- superior to ACTH in this specific syndrome.
Focal seizures, resource-limited setting: phenobarbital once daily. Counsel on sedation, enzyme induction, and Vitamin D supplementation.
Sieghart W. Structure and pharmacology of gamma-aminobutyric acid A receptor subtypes. Pharmacol Rev. 1995;47(2):181–234.
Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 2001;22(4):188–194.
doi:10.1016/S0165-6147(00)01646-1Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25(3):213–220.
doi:10.1002/ana.410250302Cereghino JJ, Cloyd JC, Kuzniecky RI. Rectal diazepam gel for treatment of acute repetitive seizures in adults. Arch Neurol. 2002;59(12):1915–1920.
doi:10.1001/archneur.59.12.1915Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591–600.
doi:10.1056/NEJMoa1107494Sankar R. GABA-A receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26(3):229–244.
doi:10.2165/11599020-000000000-00000Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring. Epilepsia. 2008;49(7):1239–1276.
doi:10.1111/j.1528-1167.2008.01561.xBourgeois BFD. Phenobarbital and primidone. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1541–1555.
Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;(6):CD001770.
doi:10.1002/14651858.CD001770.pub3Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111(10):1935–1942.
doi:10.1016/j.ophtha.2004.03.036Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. Status epilepticus and tiagabine therapy revisited. Epilepsia. 2005;46(10):1625–1632.
doi:10.1111/j.1528-1167.2005.00263.xKapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103–2113.
doi:10.1056/NEJMoa1905795Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992;14(2):292–305.
Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med. 1998;339(12):792–798.
doi:10.1056/NEJM199809173391202Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012;53(Suppl 8):40–46.
doi:10.1111/epi.12027